Clinical Trial Update: A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the gastrointestinal tolerability of PF05212389 in obese subjects, which has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• PF05212389

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 1 | Status: WITHDRAWN